| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Clinical Trials Study |
| Article Title |
Efficacy and safety of rebamipide/nizatidine in patients with erosive gastritis: A randomized, multicenter, phase 4 study
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Donghoon Kang, Myung-Gyu Choi, Ki-Nam Shim, Hye-Kyung Jung, Seung-Joo Nam, Jung Ho Park, Sang Gyun Kim, Nam-Hoon Kim, Su Jin Hong, Tae Joo Jeon, Jae Il Chung, Hang Lak Lee, Ju Yup Lee, Tae Oh Kim, Chang Min Lee, Sun Moon Kim, Jeong-Hwan Kim, Jang Eon Kim, Jeong Seop Moon, Ho Dong Kim, Wan-Sik Lee and Hong Jun Park |
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Daewoong Pharmaceutical Co., Ltd. (Seoul, Korea) |
|
|
| Corresponding Author |
Myung-Gyu Choi, MD, PhD, Professor, Department of Internal Medicine, Seoul St. Mary’s Hospital, The Catholic University of Korea, 222 Banpodaero, Seoul 06591, South Korea. choim@catholic.ac.kr |
| Key Words |
Gastritis; Erosive gastritis; Combination therapy; Rebamipide; Nizatidine |
| Core Tip |
This multicenter, randomized phase 4 trial compared the efficacy and safety of rebamipide/nizatidine combination therapy vs nizatidine monotherapy in treating erosive gastritis. The study demonstrated that the combination therapy significantly improved mucosal erosion healing compared to monotherapy, highlighting the potential benefit of combining an acid suppressant with a mucoprotective agent. While both treatment groups showed positive outcomes in managing symptoms, no significant differences in adverse events were observed. These findings suggest that combination therapy may offer a more effective approach for patients with erosive gastritis. |
| Publish Date |
2024-11-29 08:40 |
| Citation |
<p>Kang D, Choi MG, Shim KN, Jung HK, Nam SJ, Park JH, Kim SG, Kim NH, Hong SJ, Jeon TJ, Chung JI, Lee HL, Lee JY, Kim TO, Lee CM, Kim SM, Kim JH, Kim JE, Moon JS, Kim HD, Lee WS, Park HJ. Efficacy and safety of rebamipide/nizatidine in patients with erosive gastritis: A randomized, multicenter, phase 4 study. <i>World J Gastroenterol</i> 2024; 30(48): 5152-5161</p> |
| URL |
https://www.wjgnet.com/1007-9327/full/v30/i48/5152.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v30.i48.5152 |
